Richard Bernstein Advisors LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 103,670 shares of the company’s stock after purchasing an additional 5,356 shares during the period. Richard Bernstein Advisors LLC’s holdings in Johnson & Johnson were worth $12,579,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. Raymond James Financial Services Advisors Inc. raised its position in shares of Johnson & Johnson by 3.5% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 1,123,184 shares of the company’s stock valued at $136,289,000 after acquiring an additional 38,285 shares during the period. Sather Financial Group Inc raised its position in shares of Johnson & Johnson by 3.7% in the 2nd quarter. Sather Financial Group Inc now owns 11,051 shares of the company’s stock valued at $1,341,000 after acquiring an additional 399 shares during the period. Concentric Wealth Management LLC raised its position in shares of Johnson & Johnson by 3.2% in the 2nd quarter. Concentric Wealth Management LLC now owns 26,611 shares of the company’s stock valued at $3,229,000 after acquiring an additional 813 shares during the period. Narwhal Capital Management raised its position in shares of Johnson & Johnson by 2.5% in the 2nd quarter. Narwhal Capital Management now owns 40,917 shares of the company’s stock valued at $4,965,000 after acquiring an additional 1,010 shares during the period. Finally, Cardinal Capital Management raised its position in shares of Johnson & Johnson by 10.6% in the 2nd quarter. Cardinal Capital Management now owns 101,715 shares of the company’s stock valued at $12,342,000 after acquiring an additional 9,767 shares during the period. Institutional investors own 66.51% of the company’s stock.

Shares of JNJ stock opened at $145.43 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. The company has a market cap of $391.46 billion, a price-to-earnings ratio of 19.92, a P/E/G ratio of 2.28 and a beta of 0.59. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $2.03 by $0.02. The firm had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the company posted $1.90 EPS. On average, analysts forecast that Johnson & Johnson will post 8.16 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.48%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 49.32%.

A number of brokerages recently weighed in on JNJ. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $164.00 price target on the stock in a research report on Wednesday. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a research report on Wednesday, October 17th. HC Wainwright reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Raymond James increased their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Finally, Credit Suisse Group set a $149.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, October 14th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $143.90.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 8,441 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the sale, the chief accounting officer now directly owns 17,284 shares in the company, valued at approximately $2,508,772.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael E. Sneed sold 30,943 shares of the firm’s stock in a transaction that occurred on Friday, November 23rd. The stock was sold at an average price of $142.46, for a total transaction of $4,408,139.78. Following the sale, the executive vice president now owns 70,817 shares in the company, valued at $10,088,589.82. The disclosure for this sale can be found here. Insiders have sold a total of 510,544 shares of company stock worth $74,414,877 over the last 90 days. Corporate insiders own 0.22% of the company’s stock.

WARNING: This article was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2018/12/08/richard-bernstein-advisors-llc-grows-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also: Systematic Risk and Investors

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.